(S)-去甲氯胺酮的抗抑郁作用不依赖AMPA受体激活
该研究在小鼠模型中探讨氯胺酮主要代谢物(S)-去甲氯胺酮和(R)-去甲氯胺酮的抗抑郁作用及机制。结果显示(S)-去甲氯胺酮在炎症和慢性社交挫败应激模型中抗抑郁效应更强,且不依赖AMPAR激活,而是通过BDNF-TrkB-mTOR信号通路介导,同时未引起(S)-氯胺酮相关的行为异常。
要点
- (S)-去甲氯胺酮抗抑郁作用强于(R)-去甲氯胺酮,且不依赖AMPAR激活。
- 其作用经BDNF-TrkB-mTOR信号通路介导,可改善前额叶皮层和海马突触可塑性。
- (S)-去甲氯胺酮未引起(S)-氯胺酮相关的行为异常,有望成为更安全的抗抑郁药。
核心结论
- (S)-去甲氯胺酮的抗抑郁作用不依赖AMPAR激活,而是通过BDNF-TrkB-mTOR信号通路介导。
- (S)-去甲氯胺酮及其前药可能成为无(S)-氯胺酮不良副作用的新型抗抑郁药。
研究设计与样本
- 在小鼠中检查去甲氯胺酮对映体的细胞抗抑郁作用机制。
- 使用炎症模型和慢性社交挫败应激模型评估抗抑郁效果。
主要发现
- (S)-去甲氯胺酮在炎症和慢性社交挫败应激模型中抗抑郁效果强于(R)-去甲氯胺酮。
- (S)-去甲氯胺酮比(R)-去甲氯胺酮更有效改善前额叶皮层和海马树突棘密度下降及突触发生。
- AMPAR拮抗剂未阻断(S)-去甲氯胺酮的抗抑郁作用。
- 电生理数据显示(S)-去甲氯胺酮抑制NMDA受体介导的突触电流,但不增强海马神经元AMPAR介导的神经传递。
- (S)-去甲氯胺酮改善慢性社交挫败应激易感小鼠前额叶皮层BDNF-TrkB信号下调,TrkB拮抗剂和mTOR抑制剂阻断其抗抑郁作用。
临床怎么用
- (S)-去甲氯胺酮及其前药可能作为新型抗抑郁药,避免(S)-氯胺酮的行为异常副作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ketamine, an N-methyl-D-aspartate receptor antagonist, exerts robust antidepressant effects in patients with treatment-resistant depression. The precise mechanisms underlying ketamine's antidepressant actions remain unclear, although previous research suggests that alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) activation plays a role. We investigated whether (S)-norketamine and (R)-norketamine, the two main metabolites of (R,S)-ketamine, also play a significant role in ketamine's antidepressant effects and whether the effects are mediated by AMPAR. METHODS: Cellular mechanisms of antidepressant action of norketamine enantiomers were examined in mice. RESULTS: (S)-Norketamine had more potent antidepressant effects than (R)-norketamine in inflammation and chronic social defeat stress models. Furthermore, (S)-norketamine induced more beneficial effects on decreased dendritic spine density and synaptogenesis in the prefrontal cortex and hippocampus compared with (R)-norketamine. Unexpectedly, AMPAR antagonists did not block the antidepressant effects of (S)-norketamine. The electrophysiological data showed that, although (S)-norketamine inhibited N-methyl-D-aspartate receptor-mediated synaptic currents, (S)-norketamine did not enhance AMPAR-mediated neurotransmission in hippocampal neurons. Furthermore, (S)-norketamine improved reductions in brain-derived neurotrophic factor-tropomyosin receptor kinase B signaling in the prefrontal cortex of mice susceptible to chronic social defeat stress, whereas the tropomyosin receptor kinase B antagonist and a mechanistic target of rapamycin inhibitor blocked the antidepressant effects of (S)-norketamine. In contrast to (S)-ketamine, (S)-norketamine did not cause behavioral abnormalities, such as prepulse inhibition deficits, reward effects, loss of parvalbumin immunoreactivity in the medial prefrontal cortex, or baseline gamma-band oscillation increase. CONCLUSIONS: Our data identified a novel AMPAR activation-independent mechanism underlying the antidepressant effects of (S)-norketamine. (S)-Norketamine and its prodrugs could be novel antidepressants without the detrimental side effects of (S)-ketamine.
引用
- Yang C, Kobayashi S, Nakao K, et al. AMPA Receptor Activation-Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine. Biol Psychiatry. 2018. PMID: 29945718. doi:10.1016/j.biopsych.2018.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。